# Lumeda

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/lumeda

- Industry: Biotechnology
- Headquarters: Rocky Hill, US
- Website: www.lumedainc.com
- Total disclosed funding: $4.3M
- Latest round: Series A (Apr 8, 2021)
- Investors on record: 2

## About

Based in Connecticut, US, and founded in 2019, Lumeda Inc. operates as a medical technology company that develops photodynamic therapy (PDT) as a treatment for patients with non-small cell lung cancer (NSCLC) and other thoracic malignancies. The company was co-founded by Paul Sanders and Trevor MacDougall, and is backed by investors including Connecticut Innovations and Cycle Venture Partners from the Series A funding round in April 2021. 

Lumeda uses Photodynamic Therapy (PDT), a two-stage cancer treatment that involves a photosensitizer drug that collects within cancer cells and then produces cell death upon light activation. The company's DigiLum™ system is designed to be an effective therapy with minimal side effects to address disease recurrence in NSCLC tumor resection. 

Lumeda plans to further develop its PDT system, which uses artificial intelligence (AI) and proprietary software and hardware to allow controlled light dosimetry, and expects its first-in-human clinical studies to commence in the middle of 2021.

## Funding rounds

- Series A, Apr 8, 2021, $4.3M — Connecticut Innovations, Cycle Venture Partners

## Investors

- Connecticut Innovations (https://capitalatlas.ai/funds/connecticut-innovations) — Series A
- Cycle Venture Partners (https://capitalatlas.ai/funds/cycle-venture-partners) — Series A